Omeros Corp. said it raised $57.5 million after underwriters of its previously announced offering fully exercised their overallotment option.
The Seattle-based pharmaceutical company sold 4,389,311 shares at $13.10 apiece, including the additional 572,518 shares as part of underwriters' overallotment option.
Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering, which closed Dec. 9.
Omeros hopes to use the net proceeds for general corporate purposes, capital expenditures and to fund its products' clinical and preclinical trials.
Earlier this year, a European Medicines Agency committee backed Omeros' OMS721 for the treatment of a life-threatening complication of stem cell transplant called hematopoietic stem cell transplant-associated thrombotic microangiopathy.
The company is also seeking U.S. approval of the drug.